Not legal or compliance advice: Specialty pharmacy arrangements and payer contracts can implicate federal and state fraud and abuse laws, state pharmacy licensing rules, manufacturer distribution policies, and 340B program integrity requirements. Before signing an agreement, changing a data flow, or adjusting a patient-assignment practice, consult qualified legal counsel, your 340B compliance officer, an external 340B auditor, HRSA OPA, and Apexus Answers.
Covered entities increasingly find that meeting patient needs requires working alongside external specialty pharmacies and engaging more deeply with health plans. The clinical and operational reasons are well understood: limited-distribution drugs, complex therapies, prior authorization burdens, and payer-specific pharmacy network requirements. The 340B angles are more delicate.
Specialty medications represent a small share of prescriptions but a large and growing share of drug spend for patients served by covered entities.
Mission framing: Specialty pharmacy engagement should flow from patient-care needs and statutory 340B intent, not from an opportunistic focus on any particular drug class.
Standing up a fully in-house specialty pharmacy is a significant undertaking. It typically requires URAC or ACHC accreditation, payer network contracting, staffing with specialty-trained pharmacists and technicians, 24/7 clinical coverage, complex IT, and negotiations with manufacturers and hubs. Many FQHCs, Ryan White clinics, critical access hospitals, and sole community hospitals reasonably conclude that a partnership model serves patients more effectively than attempting to build internal capacity from scratch.
Eligibility determinations do not change because the drug is specialty. Common specialty failure modes include accepting referrals from non-employed, non-contracted specialists and assuming 340B eligibility; dispensing a 340B-purchased specialty drug for a prescription written during a service encounter that does not fit the entity's scope; and rolling prior authorizations through a specialist who does not have a qualifying relationship with the entity.
Documentation habit: For each specialty therapy, map the patient-eligibility logic explicitly: where is the qualifying encounter, who is the responsible provider, what record proves the prescription flows from that encounter, and what audit trail supports the determination.
Specialty workflows frequently involve hubs, copay assistance foundations, manufacturer patient-support programs, and TPAs. A typical review should cover what claims and dispensing data flow from the specialty pharmacy back to the covered entity; how the entity validates 340B eligibility before replenishment; how the arrangement handles Medicaid carve-in/carve-out status including managed Medicaid; and how exceptions are represented in reconciliation.
Specialty therapies are often supported by manufacturer copay assistance or independent foundation grants. Accumulator and maximizer programs, copay variability, and foundation eligibility rules can interact with 340B eligibility documentation.
Some manufacturers have adopted policies that affect availability of 340B pricing through contract pharmacies, including for specialty products. Policies have evolved and continue to be litigated.
Moving target: Manufacturer restrictions and related litigation change frequently. A specialty strategy that rests on a particular manufacturer's current posture is fragile.
A health plan may designate a specialty pharmacy network or a preferred pharmacy for certain conditions. Covered entities should understand whether their in-house or contract pharmacies are included, what terms govern inclusion, and how any reimbursement or effective discount mechanics work.
Shared savings, capitation, bundled payments, and quality incentive payments are increasingly common. Covered entities should consider whether metrics inadvertently reward behaviors that conflict with 340B patient definitions; how pharmacy savings from 340B purchasing are described; and whether the arrangement creates incentives to steer patients toward or away from specific pharmacies.
ACOs and similar models can align incentives across primary care, specialty care, and pharmacy. Coordinate 340B policies with ACO participation agreements, including how shared savings are calculated, who bears downside risk, and how pharmacy data is shared.
Fraud and abuse perimeter: Any arrangement that touches referrals, discounts, data sharing with referral sources, or financial flows can implicate the federal Anti-Kickback Statute, the physician self-referral law, state anti-kickback and fee-splitting laws, and state pharmacy licensure rules. Have counsel analyze the arrangement.
Pre-signature checklist:
- 340B compliance officer has reviewed patient-eligibility and data-flow terms.
- Legal counsel has reviewed fraud and abuse risk.
- Finance has modeled the reconciliation workflow and staffing implications.
- Operations has walked the patient experience end to end.
- The contract aligns with the entity's 340B P&Ps, or the P&Ps have been updated.
Specialty workflows fail quietly. Build handoffs deliberately:
Recurring failure modes:
- Misaligned incentives. Contract economics that reward volume in ways that strain patient-eligibility discipline.
- Loss of oversight. Treating the specialty partner as a black box.
- Duplicate discount risk. Incomplete Medicaid exclusion logic for managed Medicaid specialty claims.
- Brand and reputation risk. Partner conduct that the community will associate with the entity itself.
- Assumptions about manufacturer policy.
- Payer contract creep. Signing a health plan agreement whose fine print affects 340B practices.
- Referral-source entanglement.
- Orphaned patients. Transitions that leave patients without refills or contact points.
Specialty and payer partnerships warrant attention at the governance level, not just in operations.
This article is educational and does not constitute legal, tax, regulatory, compliance, or financial advice. Program rules change; verify current guidance with HRSA's Office of Pharmacy Affairs, Apexus, and qualified counsel before acting.